Fri, Mar 6, 2015, 9:15 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Progenics Pharmaceuticals, Inc. Message Board

  • malph_ralph@rocketmail.com malph_ralph May 19, 2014 12:09 PM Flag

    The time is nigh

    http://seekingalpha.com/article/2225713-nektar-therapeutics-the-time-is-nigh

    However, it appears the reason for the called advisory meeting is the currently submitted drug, Relistor, which is marketed by Salix (SLXP). Salix and its partner, Progenics (PGNX), are hoping for an expanded usage for this drug, however, the FDA has questions about the cardiac events noted in their expansion trials. In 2012, the FDA issued a CRL that requested additional testing for this drug that is delivered by injection.

    The market for an effective OIC drug is huge. There are nearly 70 million patients in the five largest markets that are being prescribed opioids for the treatment of pain. For those being prescribed such opioids, nearly 80%, or 56 million, develop OIC. Of this number, 50%, or 28 million, find that a normal laxative provides them no relief from their OIC condition.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PGNX
6.95+0.1300(+1.91%)Mar 6 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.